Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer

BACKGROUND: This was a Japanese subpopulation analysis of MONARCH 3, a randomized, double-blind, placebo-controlled phase 3 study of abemaciclib plus nonsteroidal aromatase inhibitors (NSAIs) for initial therapy for advanced breast cancer (ABC). METHODS: Eligibility included postmenopausal women wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Masato, Tokunaga, Eriko, Mori, Joji, Tanizawa, Yoshinori, van der Walt, Jan-Stefan, Kawaguchi, Tsutomu, Goetz, Matthew P., Toi, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732856/
https://www.ncbi.nlm.nih.gov/pubmed/34661821
http://dx.doi.org/10.1007/s12282-021-01295-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732856/
https://www.ncbi.nlm.nih.gov/pubmed/34661821
http://dx.doi.org/10.1007/s12282-021-01295-0

Ejemplares similares